Covance Not Cooling...
Health Care: Drugs
InterMune Inc. (ITMN: NASDAQ)
$9.99 -0.31 | -3.01%
05/17/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -150.08M | -154.77M | 122.37M | -116.02M |
| Operating Gains/Losses | -51.34M | -15.00K | 0.00 | 0.00 |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -3.00M | -2.05M | 2.12M | -711.00K |
| (Increase) Decrease in Inventories | -5.53M | -5.07M | 1.42M | -1.32M |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 11.30M | 3.99M | -2.32M | -8.64M |
| (Decrease) Increase In Other Current Liabilities | 9.34M | 3.79M | 3.46M | -4.99M |
| (Increase) Decrease In Other Working Capital | -2.15M | -831.00K | -69.35M | -17.79M |
| Other Non-Cash Items | 14.65M | 19.04M | 8.58M | 10.98M |
| Net Cash From Continuing Operations | -172.63M | -137.45M | 72.34M | -127.64M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -172.63M | -137.45M | 72.34M | -127.64M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 394.66M | 314.81M | 199.05M | 116.94M |
| Purchases of Property, Plant & Equipment | -3.19M | -22.27M | -336.00K | -354.00K |
| Acquisitions | 55.00M | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | -344.16M | -377.88M | -301.48M | -101.14M |
| Other Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | 102.31M | -85.35M | -102.76M | 15.45M |
| Issuance of Debt | 0.00 | 150.22M | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 3.64M | 139.42M | 124.00M | 65.43M |
| Repayment of Long-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Cash From Financing Activities | 3.64M | 289.64M | 124.00M | 65.43M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | -66.68M | 66.84M | 93.58M | -46.76M |
Portfolios with ITMN
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- UserChopped Liver
- ContributorHot Biotech Stocks Traded b...
- ContributorMost-Searched Stocks for th...
- Userskyisfalling
- ContributorStocks Rising On Unusual Vo...
- ContributorBreakout Stocks Of The Week...
- Contributor5 Biotech Stocks for 2012
- Contributor3 Health Care Stocks That C...
Latest ITMN Headlines from TheStreet
- ITMN Crosses Above Key Moving Average Level 04.29.13 | 04:04 pm
- J.P. Morgan Healthcare Confab Live Blog Day Three 01.09.13 | 10:01 am
- SAC's InterMune Trade Probe May Reveal Corrupted FDA Drug Review 12.10.12 | 02:12 pm
- 7 Stocks Under $10 Making Large Upside Moves 11.23.12 | 12:11 pm
- 4 Health Care Stocks Under $10 Spiking Higher 10.17.12 | 02:10 pm
- Market Preview: A Rally on Fumes 10.02.12 | 05:10 pm
- InterMune's CEO Discusses France's Economic Committee's (CEPS) Authorization Of Reimbursement Of Esbriet Conference (Transcript) 09.11.12 | 06:09 pm
- Analysts' Actions: HD SBUX MUR WAG CVS 08.15.12 | 09:08 am
- InterMune's CEO Discusses Q2 2012 Earnings - Earnings Call Transcript 07.23.12 | 02:07 pm
- Verizon, InterMune: Market Movers 07.23.12 | 12:07 pm
Press Releases for ITMN
- InterMune To Release First Quarter Financial Results On April 24 - PR Newswire 04.17.13 | 08:04 am
- Esbriet® (pirfenidone) Receives Positive Final Appraisal Determination From NICE For Idiopathic Pulmonary Fibrosis (IPF) - PR Newswire 03.20.13 | 09:03 pm
- Sean P. Nolan Joins InterMune As Executive Vice President And Chief Business Officer - PR Newswire 02.14.13 | 04:02 pm
- InterMune To Release Fourth Quarter Financial Results On February 21 - PR Newswire 02.11.13 | 08:02 am
- InterMune Announces Pricing Of Concurrent Public Offerings Of $105,000,000 Principal Amount Of Convertible Senior Notes And 13,500,000 Shares Of Common Stock - PR Newswire 01.16.13 | 01:01 am
- InterMune Announces Proposed Concurrent Public Offerings Of Common Stock And Convertible Debt - PR Newswire 01.14.13 | 04:01 pm
- InterMune Reports Preliminary Fourth Quarter 2012 Esbriet® (pirfenidone) Revenue And Other Recent Business Highlights - PR Newswire 01.03.13 | 04:01 pm
- InterMune To Present At J. P. Morgan Healthcare Conference - PR Newswire 01.02.13 | 08:01 am
- InterMune To Release Third Quarter Financial Results On November 7 - PR Newswire 10.31.12 | 08:10 am
- Health Canada Approves Esbriet® As First Treatment For Fatal Lung Disease - PR Newswire 10.02.12 | 04:10 pm
Partner Headlines for ITMN
- Court stops EU regulator releasing drug trial data - Financial Times 04.30.13 | 10:04 pm
- Drug test rules 'would eliminate biotechnology sector in UK' - Financial Times 04.21.13 | 10:04 pm
- Healthcare: Big pharma, big data - Financial Times 04.04.13 | 05:04 pm
- SAC signals further action after $614m deal - Financial Times 03.18.13 | 09:03 pm
- Four Biotech Stocks On The Clock - Seeking Alpha 02.19.13 | 09:02 am
- US authorities widen SAC Capital probe - Financial Times 02.13.13 | 10:02 pm
- 3 High Beta Liquid Small-Cap Biotechnology Stocks That Are Breaking Out - Seeking Alpha 09.17.12 | 09:09 am
- French Reimbursement for Esbriet - Analyst Blog - NASDAQ 09.13.12 | 09:09 pm
- Positive RECAP for ITMN's Esbriet - Analyst Blog - NASDAQ 09.04.12 | 07:09 pm
- InterMune Reports New Analyses from the RECAP Study of Esbriet at ERS - Benzinga 09.03.12 | 11:09 am
